Inari Medical (NARI)
(Delayed Data from NSDQ)
$49.65 USD
+2.12 (4.46%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $49.66 +0.01 (0.02%) 4:40 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Price, Consensus and EPS Surprise
NARI 49.65 +2.12(4.46%)
Will NARI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NARI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NARI
Inari Medical (NARI) Q2 Earnings Miss, Revenues Increase Y/Y
Inari Medical, Inc. (NARI) Reports Q2 Loss, Tops Revenue Estimates
NARI: What are Zacks experts saying now?
Zacks Private Portfolio Services
What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?
Revvity (RVTY) to Report Q2 Earnings: What's in the Cards?
Lower Volume Likely to Hurt GE HealthCare's (GEHC) Q2 Earnings
Other News for NARI
Inari Medical (NARI) Receives a New Rating from Deutsche Bank
Inari Medical initiated with bullish view at Deutsche Bank, here's why
Bank of America Securities Remains a Buy on Inari Medical (NARI)
Inari Medical (NARI) Gets a Buy from Morgan Stanley
Inari Medical price target lowered by $2 at Baird, here's why